- Home
- URGN
URGN
UroGen Pharma Ltd.
as 06-20-2025 3:43pm EST
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | RA'ANANA |
| Market Cap: | 181.2M | IPO Year: | 2017 |
| Target Price: | $26.81 | AVG Volume (30 days): | 5.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.42 - $18.15 | Next Earning Date: | 08-12-2025 |
| Revenue: | $91,871,000 | Revenue Growth: | 8.98% |
| Revenue Growth (this year): | 36.65% | Revenue Growth (next year): | 88.35% |
Stock Insider Trading Activity of UroGen Pharma Ltd. (URGN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Schoenberg Mark | URGN | Chief Medical Officer | Jun 8 '25 | Sell | $7.37 | 5,162 | $38,043.94 | 153,378 |
Latest UroGen Pharma Ltd. News
URGN Breaking Stock News: Dive into URGN Ticker-Specific Updates for Smart Investing
Insider Monkey
4 days ago
H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy
MT Newswires
5 days ago
HC Wainwright Upgrades UroGen Pharma to Buy From Neutral, $50 Price Target
Simply Wall St.
8 days ago
High Growth Tech Stocks in US for June 2025
TipRanks
8 days ago
FDA approves UroGen’s Zusduri for non-muscle invasive bladder cancer
BioPharma Dive
8 days ago
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans
MT Newswires
9 days ago
Scotiabank Raises UroGen Pharma Price Target to $47 From $23, Maintains Sector Outperform Rating
Business Wire
9 days ago
U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
MT Newswires
9 days ago
Urogen Pharma's Bladder Cancer Drug Receives US FDA Approval
Compare URGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "URGN UroGen Pharma Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.